Title |
Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes
|
---|---|
Published in |
Lipids in Health and Disease, September 2013
|
DOI | 10.1186/1476-511x-12-137 |
Pubmed ID | |
Authors |
Keiichi Torimoto, Yosuke Okada, Hiroko Mori, Maiko Hajime, Kenichi Tanaka, Akira Kurozumi, Manabu Narisawa, Sunao Yamamoto, Tadashi Arao, Hirofumi Matsuoka, Nobuo Inokuchi, Yoshiya Tanaka |
Abstract |
Statins are used to treat hypercholesterolemia in patients with type 2 diabetes mellitus, but many of these patients fail to achieve the target LDL-C level. Recent reports have suggested that a synergistic effect can be obtained by concomitant administration of the cholesterol absorption inhibitor ezetimibe and a statin. However, in patients with type 2 diabetes who are already being treated with satins, it remains unclear whether it is more effective to add ezetimibe or to increase the statin dose. Therefore, this study was performed to examine the effects of these two regimens on LDL-C and lipoproteins. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
France | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 1 | 1% |
Denmark | 1 | 1% |
Unknown | 70 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 10 | 14% |
Student > Bachelor | 9 | 13% |
Researcher | 8 | 11% |
Other | 7 | 10% |
Student > Postgraduate | 6 | 8% |
Other | 17 | 24% |
Unknown | 15 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 23 | 32% |
Pharmacology, Toxicology and Pharmaceutical Science | 10 | 14% |
Nursing and Health Professions | 5 | 7% |
Biochemistry, Genetics and Molecular Biology | 3 | 4% |
Agricultural and Biological Sciences | 2 | 3% |
Other | 8 | 11% |
Unknown | 21 | 29% |